Abstracts tagged "prognostic factors"

Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
Abstract Number: 1189 • 2012 ACR/ARHP Annual Meeting
Stromal Cell Markers in the Synovial Tissue of Patients with Early Arthritis and Preclinical Rheumatoid Arthritis
Yuen Kei Choi¹, Olga N. Karpus², Paul Peter Tak³, Jörg Hamann⁴, Christopher D. Buckley⁵, Andrew Filer⁶ and Danielle M. Gerlag⁷, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²1Departments of Experimental Immunology and Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, ³Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Center for Translational Inflammation Research, School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom, ⁶Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁷Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Stromal cells in synovial tissue (ST) of patients with arthritis may have an important role in the initiation and persistence of the inflammatory infiltrate.…
Abstract Number: 1049 • 2012 ACR/ARHP Annual Meeting
The Prevalence of the Ultrasonographic Positive Power Doppler Synovitis Is High and Predicts the Risk of Relapse and Structural Progression in Rheumatoid Arthritis in Clinical Remission: A Systematic Literature Review and Meta Analysis
Huong Nguyen¹, Adeline Ruyssen-Witrand¹, Arnaud L. Constantin¹, Violaine Foltz², Frédérique Gandjbakhch³ and Alain G. Cantagrel¹, ¹Rheumatology, Purpan University Hospital, Toulouse, France, ²APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ³Department of Rheumatology, APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France
Background/Purpose: Ultrasonography (US) can detect synovitis in patients with rheumatoid arthritis (RA) more sensitively than clinical examination either in active disease or in remission.1, 2…
Abstract Number: 770 • 2012 ACR/ARHP Annual Meeting
Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort
Ruediger Mueller¹, Toni Kaegi¹, Axel Finckh² and Johannes von Kempis¹, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset…
Abstract Number: 399 • 2012 ACR/ARHP Annual Meeting
Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)
Yoichiro Haji¹, Mitsumasa Kishimoto¹, Ryo Rokutanda¹, Sachiko Ohde², Gautam A. Deshpande³, Yuri Ohara¹, Chisun Min¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi¹, Akira Takeda⁴, Yukio Matsui¹, Masato Okada¹ and Shigeto Tohma⁵, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St.Luke's Life of Science Institute, Tokyo, Japan, ³Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ⁴Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is now the goal of therapy to reduce joint damage and disability, and maintain or improve…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].